HOT TOPICS
LATEST
TOP STOCKS
SECTORS
MINING & RESOURCES
BIOTECH & PHARMA
TECHNOLOGY
OIL, GAS & ENERGY
INDUSTRIALS & JUNIORS
IPOs
TOOLS
STOCK SUMMARY
ANNOUNCEMENTS
VOLUME STOCKS
DIRECTOR TRADES
SECTOR TRACKER
MARKET DATA
ULTIMATE GUIDES
VIDEOS
PODCAST
EVENTS
SUBSCRIBE
English
(
English
)
中文
(
Chinese
)
Search
EN
|
中文
Small Caps
HOT TOPICS
LATEST
TOP STOCKS
SECTORS
MINING & RESOURCES
BIOTECH & PHARMA
TECHNOLOGY
OIL, GAS & ENERGY
INDUSTRIALS & JUNIORS
IPOs
TOOLS
STOCK SUMMARY
ANNOUNCEMENTS
VOLUME STOCKS
DIRECTOR TRADES
SECTOR TRACKER
MARKET DATA
ULTIMATE GUIDES
VIDEOS
PODCAST
EVENTS
SUBSCRIBE
English
(
English
)
中文
(
Chinese
)
BIOTECH & PHARMA
BIOTECH & PHARMA
HOT TOPICS
INDUSTRIALS & JUNIORS
MINING & RESOURCES
OIL, GAS & ENERGY
TECHNOLOGY
UPCOMING FLOATS
Biotech and pharma stocks listed on the ASX.
Incannex Healthcare officially owns world’s largest portfolio of patented medicinal cannabis drug formulations
August 5, 2022
Incannex to scale up manufacture of neuroprotective cannabinoid combination drug IHL-216A
August 2, 2022
InhaleRx fast-tracks development of inhaled cannabinoid-based formulations for panic disorder and CRPS
August 1, 2022
PharmAust opens door to billion-dollar markets, following MPL trial successes
August 1, 2022
Incannex Healthcare progresses cannabinoid and psychedelic medicine programs
July 27, 2022
Incannex Healthcare to begin phase 1 clinical trial for IHL-675A following ethics approval
July 21, 2022
PharmAust focuses in on monepantel trials for motor neurone disease and canine cancer
July 20, 2022
Wellnex Life teams up with OneLife Botanicals to penetrate Australia’s medicinal cannabis market
July 18, 2022
‘World-leading’ brain cancer experts headline Kazia Therapeutics’ new scientific advisory board
July 12, 2022
Argenica Therapeutics reports positive findings from peer-reviewed study of stroke drug ARG-007
July 8, 2022
Botanix Pharmaceuticals prepares new drug application for novel gel to treat excessive underarm sweating
July 7, 2022
Kazia Therapeutics awarded US FDA rare drug designation for paxalisib in childhood brain cancer
July 7, 2022
Invex Therapeutics in strong position to launch Presendin trials
July 6, 2022
Invex Therapeutics approved to start Presendin phase three clinical trial in Australia
July 4, 2022
Kazia Therapeutics reports good half-year progress despite market challenges
June 30, 2022
Invex Therapeutics gains UK regulatory approval for clinical trial of Presendin to treat idiopathic intracranial hypertension
June 29, 2022
Kazia Therapeutics collars US FDA orphan drug designation for paxalisib in a highly aggressive childhood brain cancer
June 17, 2022
Greenlab joins forces with Helius Therapeutics to develop targeted medicinal cannabis treatments
June 15, 2022
Kazia Therapeutics presents ‘positive data’ on paxalisib in childhood brain cancers
June 14, 2022
Prescient Therapeutics unveils high performance cell therapy technology CellPryme-M
June 8, 2022
Kazia Therapeutics expands paxalisib study to include secondary brain tumours from breast cancer
June 8, 2022
Load more